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under the terms of t
share the work provIntroduction: Direct measurement of antiretroviral treatment (ART) program indicators
essential for evidence-based planning and evaluation – especially HIV incidence,
population viral load, and ART eligibility – is rare in sub-Saharan Africa.
Design/methods: To measure key indicators in rural western Kenya, an area with high
HIV burden, we conducted a population survey in September to November 2012 via
multistage cluster sampling, recruiting everyone aged 15–59 years living in 3330
randomly selected households. Consenting individuals were interviewed and tested for
HIV at home. Participants testing positive were assessed for CD4þ cell count and viral
load, and their infections classified as either recent or long term based on Limiting
Antigen Avidity assays. HIV-negative participants were tested by nucleic acid ampli-
fication to detect acute infections.
Results: Of 6833 household members eligible for the study, 6076 (94.7% of all women
and 81.0% of men) agreed to participate. HIV prevalence and incidence were 24.1%
[95% confidence interval [CI] 23.0–25.2] and 1.9 new cases/100 person-years (95% CI
1.1–2.7), respectively. Among HIV-positive participants, 59.4% (95% CI 56.8–61.9)
were previously diagnosed, 53.1% (95% CI 50.5–55.7) were receiving care, and 39.7%
(95% CI 37.1–42.4) had viral load less than 1000 copies/ml. Applying 2013 WHO
recommendations for ART initiation increased the proportion of ART-eligible people
from 60.0% (based on national guidelines in place during the survey; 95% CI 57.3–
62.7) to 82.0% (95% CI 79.5–84.5). Among HIV-positive people not receiving ART,
viral load increased with decreasing CD4þ cell count (500–749 vs. 750 cells/ml,
adjusted mean difference, 0.40 log10 copies/ml, 95% CI 0.20–0.60, P<0.01).
Conclusion: This study demonstrates how population-level data can help optimize HIV
programs. Based on these results, new regional programs are prioritizing diagnosis and
expanding ART eligibility, key steps to reach undetectable viral load.
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In 2012, more than 10 million people living with HIV in
sub-Saharan Africa were receiving antiretroviral therapy
(ART) [1], which dramatically reduces both morbidity
and mortality [2–4]. In 2011, the HPTN 052 study
showed that early initiation of ART prevents sexual
transmission at the individual level [5], confirming earlier
observational findings [6,7]. However, the hypothesis that
increasing the proportion of HIV-positive individuals
with an undetectable viral load will gradually reduce HIV
incidence in the population has yet to be conclusively
demonstrated. This is partially because evaluating the
impact of ART programs on incidence is a complex
undertaking, requiring repeated measurements of inci-
dence and viral suppression in a population over time, and
has therefore rarely been done. The resulting ‘data gap’
has been identified by the WHO and other leading
international organizations and advocacy groups as a
major hurdle not only to assessing the population-level
impact of ART but also to monitoring the effectiveness of
HIV treatment programs [8,9].
To help plug the data gap, WHO recently published a
framework of metrics for evaluating ‘treatment as
prevention’ programs [10]. Beyond the usual monitoring
of treatment cohorts, it recommends conducting periodic
population surveys in the community to measure HIV
incidence, prevalence, and retention of patients along the
continuum of care (often called the ‘cascade of care’) from
initial diagnosis through linkage to care, ART initiation
and finally, viral suppression. Such studies are aimed at
identifying weak points in the cascade when patients are
lost from treatment, preventing them from achieving
undetectable viral load [11]. Indeed, reaching a high level
of viral suppression at the population level (a good proxy
for both transmission risk and ART effectiveness [9,12])
requires good outcomes at every step along the care
continuum [10,13]. Carefully monitoring loss along the
cascade is critical for ART programs so they can prioritize
interventions likely to have the most impact.
Despite their complexity, such population surveys are
increasingly feasible because HIV incidence can be
estimated directly using serologic assays that distinguish
recent from established HIV infections [14–16]. These
assays are also simpler, cheaper, and easier to implement
than traditional approaches for measuring incidence by
monitoring an incident cohort over a defined period [14].
Equally important, population surveys can directly
measure ART eligibility in a population. To monitor
the quality of ART coverage and to prepare for
implementing new ART guidelines, it is essential to
assess the numbers of people needing ART. While many
studies have quantified patient losses at key steps along the
cascade [17], few measured each step in a sub-Saharan
African population.Ndhiwa is a subcounty within the County of Homa-Bay
in Kenya and has a population of 172 000 inhabitants. It is
located in the Nyanza region, the area of Kenya most
affected by HIV, with an estimated prevalence of 15.1% in
2011 [18]. To directly evaluate key HIV indicators and the
current national response, and thereby to inform
planning, budgeting and setting priorities for regional
programming, Kenya’s Ministry of Health (MoH) and
Médecins Sans Frontières conducted a population survey
in September to November 2012 to simultaneously
measure HIV incidence, prevalence and all steps in the
cascade of care.Material and methods
Study design
The Ndhiwa HIV Impact in Population Study was a
representative population-based survey conducted from
September to November 2012 in Ndhiwa, Kenya. It used
a two-stage sampling design to randomly select 3300
households. In the first stage, 165 clusters were selected
from a list of Ndhiwa’s 402 enumeration areas (admin-
istrative units defined by the Kenyan National Bureau of
Statistics for the purpose of census-taking) obtained from
the 2002 national census. Each cluster was one
enumeration area. At the second stage, 20 households
were randomly selected from each cluster. All residents
aged 15–59 years were considered eligible and, after
being informed about the study as described below,
invited to participate.
Ethical approvals
Ethical approval was obtained in Kenya from the Kenya
Medical Research Institute Ethical Review Committee
(KEMRI, ref 347) and in France, from the ‘Comité de
Protection des Personnes d’Ile de France’ (CPP, ref
12056). Written consent for participating in the study and
undergoing HIV testing was obtained from each
participant prior to the survey interview.
Community participation and questionnaire
Community mobilization was done prior to the survey in
two steps. First, the study team met with all local leaders;
then they visited each selected enumeration unit to
directly mobilize the community, which involved
distributing information leaflets about the survey and
each person’s right to refuse to participate. Community
members were told that the survey was about HIV and
that they would be tested for HIV if they agreed
to participate.
The questionnaire was based on the MACRO ques-
tionnaire framework used for the Demographic and
Health Survey, a design meant to ensure maximal
comparability of results with Demographic and Health
Survey findings [19,20]. The questionnaire was translated
into Luo, the main language spoken in the county, and
Cascade of HIV care and population viral suppression Maman et al. 1559then back-translated as a quality check. It was pretested in
the community in early September 2012.
Questionnaires collected socioeconomic, behavioral, and
medical information about each participant. Men self-
reported their circumcision status using graphics tools,
whereas women reported their history of births, antenatal
care and, if HIV-positive, PMTCT care. Participants were
also asked about previous HIV testing and the result of
their most recent test.
Cascade of care steps and definitions
The first four stages were all self-reported by participants.
Stage 1, HIVawareness, was defined as a history of at least
one positive HIV test prior to the survey. Linkage to care
(stage 2) was defined as at least one medical contact for
HIV care after a positive test, whereas retention in care
(stage 3) was defined as an HIV-related medical
consultation within the prior 6 months. ART use (stage
4) was also self-reported. The last stage, viral load
suppression, was defined as a viral load below
1000 copies/ml as measured from the sample collected
during the survey visit and tested as described below.
ART eligibility was assessed according to the Kenyan
2010 ART guidelines [21], which considered an HIV-
positive individual eligible for ART if he or she had ever
started ART (except for PMTCT) or had a CD4þ cell
count 350 cells/ml or less. We also assessed eligibility
based on the 2013 WHO ART guidelines, which
recommend initiating ARTat CD4þ cell count 500 cells/
ml or less and for all pregnant and breastfeeding women
regardless of CD4þ cell count [22].
Laboratory procedures
Participants were tested for HIV at home using a serial
rapid testing algorithm according to Kenyan national
guidelines, using Determine Rapid HIV1/2 Antibody
(Abbott Laboratories, Abbott Park, Illinois, USA)
followed by Unigold Rapid HIV Test (Trinity Biotech,
PLC, Bray, Co Wicklow, Ireland). Participants with
discordant or equivocal results were tested by ELISA to
confirm their status.
For all participants who tested positive, a venous blood
sample was collected at home for CD4þ cell count,
performed using the PIMA CD4þ cell counter (Alere,
PIMA, Jena, Germany), and for both viral load (COBAS
Amplirep/Cobas Taqman platform; Roche Diagnostic
System, Branchburg, New Jersey, USA) and recent
infection using the Limiting Antigen Avidity (LAg) EIA
test (Sedia Biosciences Corp., Portland, Oregon, USA).
LAg is a serological assay that detects increasing avidity
antibody maturation following seroconversion and can
detect recent HIV-1 infections (those for which
seroconversion occurred during the past 130 days; 95%
CI 118–142) [23]. To be classified as recently infected, a
participant must have a normalized optical density
threshold of 1.5 or below, report not being on ART,and have a detectable viral load (>300 copies/ml).
Therefore, the overall mean duration of recent infection
in our algorithm was 158 days (95% CI 146–170) as it
included the 130 days of the LAg and 28 days window
period of the Nucleic Acid Amplification Testing
(NAAT). The false recent rate of the recent infection
testing algorithm, which is the proportion of the
nonrecent HIV population incorrectly classified as recent,
was estimated at 0.5% (95% CI 0.01–1.0) [24].
To identify infections prior to seroconversion (i.e., acute
infection), samples from all individuals testing negative for
HIV by serological tests underwent NAATon a COBAS
Amplirep/Cobas Taqman platform (Roche Diagnostic
System) from a finger prick of whole blood preserved on a
dried blood spot. The number of newly acquired
infections was obtained by adding the number of
NAAT-detected acute infections to LAg-identified
recent infections.
Data management and analysis
Data were entered and checked using Epidata version 3.1
and analyzed using Stata 13 (Stata Corp., College Station,
Texas, USA). All data were anonymized. Descriptive
analyses were weighted to account for sampling design
and are presented here with 95% CIs. We estimated HIV
incidence rate per 100 person-years with 95% CIs using
the McWalter and Welte formula [25]. To calculate the
mean population viral load we log-transformed individual
viral load. The proportion of the population classified as
virologically suppressed was defined as the ratio of the
number of suppressed individuals to the number of
individuals tested positive. Two-sample t test and Pearson
chi-square statistics were used to compare continuous and
categorical descriptive outcomes, respectively. To identify
risk factors associated with viral load among those not
receiving ART, we used a weighted multivariate linear
regression model and considered people not on ART.Results
Inclusion and characteristics of the study
population
The study was conducted between September and
November 2012 and collected information on 3300
households (Fig. 1). A total of 3966 women and 2867
men were eligible for the study. Of this group, 3755
women (94.7%) and 2321 men (81.0%) agreed to
participate and were tested for/underwent HIV. Among
participating individuals, 3154 (51.9%) were 18–34
years old.
HIV prevalence and incidence
HIV prevalence and incidence results are presented in
Table 1. Of the 6076 participants tested for HIV, 1457
were HIV-positive. Overall HIV prevalence was 24.1%
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Fig. 1. HIV Cascade of care, Ndhiwa, Kenya, 2012.(95% CI 23.0–25.2) and was higher for women (26.7%,
95% CI 25.3–28.3) than for men (19.8%, 95% CI 18.2–
21.6, P< 0.01), and more than double in those 30–44
years old compared with those aged 15–29 (34.7%; 95%
CI 32.4–30.8 vs. 16.8%, 15.4–18.1, P< 0.01). Con-
cerning marital status, prevalence was 4.0% (95% CI 3.0–
5.3) among those never married and 55.6% (95% CI
51.0–60.0) among widowed participants. Prevalence was
significantly lower among pregnant or breastfeeding
women than among women who were neither (21.7 vs.
29.8%, P< 0.01), and among medically circumcised
compared with uncircumcised men (14.9 vs. 21.5%,
P< 0.01).
Of the HIV-positive participants, 11 were NAAT-positive
(and rapid diagnostic test negative), that is, had acute
infections, while 31 patients were classified as recently
infected using the LAg test algorithm. Overall HIV
incidence was estimated at 1.90 new cases/100 person-
years (95% CI 1.11–2.70). Incidence in women was more
than twice that in men (2.47 new cases/100 person-years,
95% CI 1.36–3.58 vs. 1.06 new cases/100 person-years,
95% CI 0.18–1.94) and nearly doubled in people aged
15–29 compared with 45–59 year olds (1.98 new cases/
100 person-years [95% CI 1.12–2.85] vs. 1.03 new cases/
100 person-years [95% CI 0–2.39]). Among men, HIVincidence among uncircumcised men was over four-fold
more in uncircumcised compared with medically
circumcised men (1.20 [95% CI 0.08–2.33] vs. 0.24
new cases/100 person-years [95% CI 0.00–1.28]).
Cascade of care and ART eligibility
The proportions of HIV-positive people retained at each
key step in the cascade of care are shown in Fig. 2. Of
1457 HIV-positive individuals identified in our survey,
complete information regarding CD4þ cell count and
viral load was recorded for 1365 (93.7%). Of this latter
group, 59.4% (95% CI 56.8–61.9) reported in the survey
interview that they had previously been diagnosed as
HIV-positive; this proportion was higher in women than
in men (61.6 vs. 54.6%, P¼ 0.02), as was the proportion
of HIV-positive women reporting retention in care (55.3
vs. 48.3% for men, P¼ 0.02). However, there was no
significant sex difference in the proportions of HIV-
positive participants on ART (39.0% [95% CI 35.9–42.2]
for women vs. 40.9% [95% CI 36.3–45.7] for men,
P¼ 0.51) or among HIV-positive participants showing
viral suppression (39.3% [95% CI 36.1–42.6] for women
vs. 40.6% [95% CI 35.8–45.6] for men, P¼ 0.67; overall
39.7% [95% CI 37.1–42.4]).
The proportion of HIV-positive individuals in need of
ART based on the guidelines in effect in Kenya at the
time of the study (2010 national guidelines: CD4þ cell
count less than 350 cells/ml and PMTCToption A), and
those eligible under the 2013 WHO guidelines (CD4þ
cell count< 500 cells/ml and PMTCT option Bþ), are
shown in Table 2. Overall, 60.0% (95% CI 57.3–62.7) of
the HIV-positive population was eligible using the 2010
Kenyan guidelines. A higher proportion of men than
women was in need of treatment (65.0%, 95% CI 60.1–
69.6 vs. 57.8%, 95% CI 54.4–61.0, P¼ 0.02). Under the
2013 WHO guidelines, 83.0% (95% CI 80.2–85.4) of
HIV-positive women and 79% (95% CI 74.9–82.7) of
HIV-positive men would be eligible for treatment.
Calculating the ART coverage rate (proportion of those
receiving ART divided by those eligible) based on the
newer WHO guidelines, coverage dropped from 69.1%
(95% CI 65.8–72.2) to 50.7% (95% CI 47.8–50.7).
Among participants not initiated on ART, the median
CD4þ cell count was high, at 519 [IQR 341–714] for
women and 436 [IQR 279–635] for men.
Population viral load
Distribution of the population viral load stratified by
ART use and awareness of HIV status is shown in
electronic supplementary Fig. 1. Of the 1365 HIV-
positive individuals with viral load data, the proportion
showing viral suppression (<1000 copies/ml) was 39.7%
(95% CI 37.1–42.4). If the total population tested for
HIV is considered regardless of HIV status, 889 of 6076
individuals (13.7%, 95% CI 12.8–14.6) had a viral load
more than 1000 copies/ml. Among those on ART (578
individuals, median time on ART 22.9 months), the
Cascade of HIV care and population viral suppression Maman et al. 1561








(new cases per 100 PY(95% CI)
Sex
Male 2321 457 19.8 (18.2–21.6) 1.06 (0.18–1.94)
Female 3755 1000 26.7 (25.3–28.3) 2.47 (1.36–3.58)
Age (years)
15–29 3154 533 16.7 (15.4–18.1) 1.98 (1.12–2.85)
30–44 1786 614 34.7 (32.4–30.8) 1.51(0.06–2.96)
45–59 1136 310 27.9 (25.3–30.8) 1.03 (0.00–2.39)
Marital status (missing: 36)
Never married 1291 49 4.0 (3.0–5.3) 1.62 (0.44–2.80)
Married/living together 4133 1095 26.4 (25.1–27.8) 2.30 (1.26–3.33)
Divorced/separated 105 28 28.6 (20.3–38.6) NA
Widowed 511 279 55.6 (51.0–60.0) NA
Education (missing: 4)
Primary or less 5046 1283 25.6 (24.4–26.9) 1.91 (1.04–2.79)
Secondary or higher 1026 174 16.8 (14.6–19.4) 1.86 (0.28–3.45)
History of HIV testing (missing: 19)
Never tested 1224 191 26.2 (24.9–27.5) 1.03 (0.00–2.15)
Ever tested 4833 1266 16.3 (14.2–18.7) 2.16 (1.22–3.11)
Residence Ndhiwa (missing: 3)
<10 years 1422 333 23.3 (21.1–25.7) 3.79 (1.80–5.79)
10 years 4651 1089 24.3 (23.1–25.6) 1.27 (0.52–2.02)
Mobility (nights outside/month) (missing: 19)
0 2009 367 18.5 (16.8–20.3) 2.15 (0.93–3.38)
1–5 3177 840 26.8 (25.2–28.5) 1.72 (0.68–2.75)
6þ 871 245 24.1 (23.0–25.2) 1.56 (0.00–3.38)
Pregnant or breastfeedinga
Yes 1411 312 21.7 (19.6–24.1) 2.70 (1.00–4.40)
No 2344 688 29.8 (27.8–31.7) 2.34 (0.97–3.71)
Medical circumcisionb (missing: 15)
Yes 563 84 14.9 (12.1–18.3) 0.24 (0.00–1.28)
No 1743 372 21.5 (19.5–23.6) 1.20 (0.08–2.33)
Total 6076 1457 24.1 (23.0–25. 2) 1.90 (1.11–2.70)
CI, confidence interval; PY, person-years.
aOnly women.
bOnly men.proportion showing suppression rose to 83.6% (95% CI
80.0–86.1). No significant difference in viral load
distribution was found between those aware of their
status but not on ART and those undiagnosed at the time
































Fig. 2. HIV Cascade of care, Ndhiwa, Kenya, 2012.Overall mean and median population viral load
measurements were 2.87 log10 copies/ml (95% CI
2.75–3.00) and 7272 copies/ml [IQR 0–75200],
respectively (Table 3). To identify associations between
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ART eligibility (% þ95% CI)
Women 57.8 (54.4–61.0) 83.0 (80.2–85.4)
Men 65.0 (60.1–69.6) 79.0 (74.9–82.7)
Total 60.0 (53.3–62.7) 81.7 (74.5–83.8)
ART coverage (% þ95% CI)
Women 70.3 (66.2–74.2) 49.0 (45.4–52.6)
Men 66.6 (60.7–72.1) 54.8 (49.3–60.3)
Total 69.1 (65.8–72.2) 50.7 (47.8–50.7)
ART, antiretroviral treatment; CI, confidence interval.ART, we performed a multivariate analysis using a
weighted linear model. Men had higher viral load than
women (adjusted mean difference 0.27 log10 copies/ml;
95% CI 0.12–0.42) after accounting for all variables
included in the model. Viral load was also strongly
associated with CD4þ cell counts, increasing as CD4þ
cell count decreased. For example, individuals with
CD4þ cell count between 500 and 749 CD4þ cells/ml
had a mean viral load that was 0.40 log10 copies/ml (95%
CI 0.20–0.60, P< 0.01) higher than those with CD4þ
cell count 750 cells/ml at least. The difference is highest
for individuals with CD4þ cell count less than 200 cells/
ml at 0.91 log10 copies/ml (vs. CD4
þ cell
count 750 cells/ml; 95% CI 0.65–1.18, P< 0.01).
Age was not associated with viral load in the multivariate
model (30–44 vs. 15–29 years old, 0.05 log10 copies/ml;
95% CI 0.09–0.20; P¼ 0.46).Discussion
This study reports the direct measurement of HIV
incidence and key steps along the cascade of care in a rural
district in Nyanza province, Kenya. To our knowledge, it
is among the first reports from sub-Saharan Africa to
directly evaluate incidence and cascade of care, from
diagnosis to ART eligibility and viral suppression, in a
single population-based study.
Most HIV programs in sub-Saharan Africa are based on
relatively limited data, often extrapolated from selected
populations and/or sites, or from modeling studies.
WHO and other stakeholders have been urgently calling
for better evidence to support program planning and
assessment of populations and how many people need
which services, and how many are receiving them. These
data are essential for evaluating the impact of treatment-
as-prevention strategies on reducing the rate of new
infections, and ultimately curbing the epidemic. Several
countries in the region, including Kenya, Uganda, and
Swaziland, have begun implementing population studies
to measure these indicators [26,27].
Our findings clarified some prevailing notions about the
HIV epidemic in the region and brought a far moredetailed picture of the cascade, while also offering
several surprises.
HIV incidence in the adult population of the Ndhiwa
subcounty, which we estimated at 1.9 new cases per
100 person-years, was four times higher than the national
estimate derived from the 2012 Kenya AIDS Indicator
survey, highlighting (among other factors) the hetero-
geneous distribution of the HIVepidemic in Kenya [18].
This figure is relatively similar to the estimate of 2.4 new
cases/100 person-years for Homa-Bay county, where
Ndhiwa is situated, produced in late 2011 using spectrum
mathematical modeling [28]. Incidence was higher for
women and young adults – a trend also seen in the
Swaziland and Uganda surveys, where the high incidence
was also driven mainly by the incidence in young women
[29,30].
One key finding was that 60.3% of the HIV-positive
population, representing 13.8% of the overall adult
Ndhiwa population, had a viral load above 1000 copies/
ml. Only the Swaziland HIV measurement survey used
similar methodology, and it found similar results [31].
Compared with previous efforts in other settings to
measure community viral load from routinely available
data – that is, data only from people in care – our estimate
is based on viral load measurements across the entire HIV-
positive population, regardless of linkage to care and ART
status [12,32]. Measuring the proportion of individuals
with high viral load in an entire community was recently
described as a strategy for overcoming bias inherent to
routinely available data [9]. Our study also includes people
with acute infection, which is associated with much
higher viral load levels [33,34].
By studying risk factors associated with viral load among
people not receiving ART, this study also provides new
information to help identify individuals most at risk of
transmitting HIV. One such group is people with CD4þ
cell count levels in the 500–749 CD4þ cells/ml range,
who are not eligible for ARTunder either Kenyan (2010)
or WHO (2013) guidelines but who we found to have
higher viral load levels proportional to their decreased
CD4þ cell count. Although this relationship between
CD4þ cell count levels and viral load is well characterized
in Western settings [35,36] and in a sub-Saharan African
population [37], this finding suggests that individuals with
CD4þ cell count between 500 and 749 cells/ml could be
at higher risk for transmitting HIV and progressing to
AIDS than those with higher CD4þ cell counts. Men in
general could also be at higher risk for transmitting
(relative to women), with overall viral load more than
twice that of women, even when CD4þ cell count and
age were accounted for – again, findings previously
reported in Western cohorts [38,39]. In sub-Saharan
Africa, at population level, two studies found no gender
differences in viral load [37,40] whereas one did [17].
These data provide valuable support for a focused
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1564 AIDS 2015, Vol 29 No 12programmatic approach targeting individuals most at risk
for transmitting HIV.
Our data on the cascade of care found that patients were
lost mostly at two points: HIV testing and ART initiation.
First, 40% of all HIV-positive individuals were unaware of
their status, a similar figure to those from the most recent
Kenya AIDS Indicator survey and from Swaziland
[18,27]. This represents the biggest loss along the cascade
and indicates the urgent need to expand testing in
Ndhiwa, where 10% of all adults have undiagnosed HIV.
Second, although 56.2% of the HIV-positive population
reported being in care, only 42.2% were on ART. This
discrepancy can be explained by the district’s ART
eligibility requirements (initiation at 350 CD4þ cells/ml
and PMTCT option A), which exclude many HIV-
positive people. If the WHO 2013 guidelines (initiation at
500 cells/ml and PMTCToption Bþ) were implemented
in Ndhiwa, the proportion of HIV-positive individuals
eligible for ART would rise from 60 to 82%.
Our estimate that 60% of the total HIV-positive
population was in need of ART is higher than that
derived from the mathematical model (42%) used in
program planning by Kenya’s Ministry of Health, in
Homa-Bay, the county where Ndhiwa is situated [28].
We believe that certain indicators measured in population
studies, including ART eligibility and population
distribution of viral load and CD4þ cell count should
be regularly used to strengthen assumptions used in
mathematical models for predicting the potential impact
of different interventions. It was already done with the
Spectrum model that used the CD4þ cell count
distribution of the 2007 Kenya Incidence Survey to
strengthen its assumptions [41].
This study presents some limitations. Because of the
cross-sectional observational design, no causal inference
can be made between HIV incidence and population viral
load. Furthermore, other than the laboratory data, the
information we collected was self-reported by partici-
pants, which can lead to recall bias and misclassifications.
This was seen, for example, during the clinical trial
HPTN 052, where approximately 3% of the participants
who did not self-report using ART nevertheless had
detectable blood levels of ART [42]. Finally, incidence
was calculated based on recent infection assays which can
have with poorer outcomes with HIV sub-type D, known
to be common in this part of Kenya [43].
Based on the unexpectedly high incidence and prevalence
rates found in this survey, Kenya’s MoH, together with
Médecins Sans Frontières, launched several new initiat-
ives in Ndhiwa in early 2014 to strengthen the two
weakest points in the cascade of care – that is, improving
HIV diagnosis and expanding ART eligibility by
implementing the 2013 WHO guidelines. The survey
will be repeated four years after the initial one presentedhere, to assess whether these initiatives have led to
improved programmatic outcomes and to decreasing HIV
incidence. Similarly, population-based studies that
measure these same indicators in other high prevalence
settings should provide useful information for identifying
the weakest points in the cascade of care and prioritizing
programs to address them, thereby increasing impact on
patient outcomes and on realizing the promise of
treatment as prevention strategies.Acknowledgements
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